Primer: Summit Therapeutics (SMMT US) - Sep 2025
Summit Therapeutics is a clinical-stage biopharmaceutical company singularly focused on its lead asset, ivonescimab (SMT112), a novel,...
160 Views
3SBio Inc (1530 HK): Licensing Deal a Market Hit; Will It Continue?
3SBio signed $6B outlicensing deal with Pfizer for SSGJ-707, resulting in spectacular rally in 3SBio shares. Global trial initiation of SSGJ-707...
245 Views
Akeso Biopharma (9926 HK) Placement - We Are Now at a Critical Point
Akeso's potential success in HARMONi-2 study may be already factored into high valuation. Investors need to be cautious about this placement,...
281 Views
China Healthcare Weekly(Jul.13)- AstraZeneca-Summit $15bn Deal, IFBH Shares Decline Is Far from Over
High-value medical device industry is on the brink of a policy turning point. There's many uncertainties about AstraZeneca-Summit $15bn deal. IFBH...
705 Views
Biopharma Week in Review Large M&A and Licensing Deals Provide a Boost
Gene and cell therapy (NTLA, BEAM, CRSP) got a boost, as the heads of the HHS, FDA, CBER, NIH, and CDC expressed support for faster rare disease...
260 Views